It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

GLYCATED ALBUMIN: AN INDICATOR FOR GLYCEMIC CONTROL | Mukherjee | International Journal of Bioassays

GLYCATED ALBUMIN: AN INDICATOR FOR GLYCEMIC CONTROL

Brijesh Mukherjee

Abstract


The progressive complications of unmanaged diabetes include heart disease, blindness, kidney failure, amputation of extremities due to circulation problems, and nerve disorders, as well as other chronic conditions. Decades of research have established that prolonged exposure to excess glucose is the cause of diabetes complications, and that long-term control of blood glucose levels is required to avoid or lessen the damage caused by excess glucose. The process of protein glycation is now understood to be both a marker for the progress of diabetes complications and an underlying cause of many of the most serious complications. Diabetes monitoring for protein glycation, an essential element for the long-term control of the complications of diabetes mellitus, is currently managed by a combination of daily self-monitoring of blood glucose (SMBG) measurements and physician-assessed hemoglobin A1c (A1C) levels every 3–6 months. Short term methods like self-monitoring of blood glucose and long term methods like measurement of HbA1c have limitations.  Various researchers have identified glycated albumin (GA) as the ideal marker for an intermediate index to measure glycation.

Keywords


Diabetes Mellitus, Glycated Albumin, Blood Glucose

Full Text:

PDF

References


American Diabetes Association All about diabetes

http://wwwdiabetesorg/about-diabetesjsp (accessed 9/2006, 2009)

Nelson DL, Cox MM, Eds; In Lehninger Principles of Biochemistry W H Freeman and Company: New York, 2005, pp 1119.

Bennet ST, Todd JA, Human type 1 diabetes and the insulin gene: Principles of mapping polygenes, Annu Rev Genet, 1996, 30, 343-370.

Turner RC, Cull CA, Frighi V, Holman RR, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus J Am Med Assoc 1999, 281, 2005-2012.

Hartog JWL, Voors AA, Bakker SJL, Smit AJ, Veldhuisen DJV, Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications Eur J Heart Fail 2007, 9, 1146-1155.

Olijhoeka JK, Graafb YVD, Bangaa JD, Algrab A, Rabelinka TJ, Visserena FLJ, The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm Eur Heart J 2004, 25, 342-348.

Perneger TV, Brancati FL, Whelton PK, Klag MJ, End-stage renal disease attributable to diabetes mellitus Ann Intern Med 1994, 121, 912-918.

Turk Z, Misur I, Turk N, Temporal association between lens protein glycation and cataract development in diabetic rats, Acta Diabetol, 1997, 34, 49-54.

Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA, Lower-extremity amputation in people with diabetes Epidemiology and prevention, Diabetes Care, 1989, 12, 24-31.

Thornalley PJ, Langborg A, Minhas HS, Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose, Biochem J, 1999, 344, 109-116.

Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, RAGE signaling sustains inflammation and promotes tumor development, J Exp Med, 2008, 205, 275-285.

Stern DM, Yan SD, Yan SF, Schmidt AM, Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes, Ageing Res Rev, 2002, 1, 1-15.

Brownlee M, Negative consequences of glycation, Metab Clin Exp, 2000, 49, 9-13.

Jansirani Anathanaryanan PHA, comparative study of lens protein glycation in various forms of cataracht, Indian J Clin Biochem, 2004, 19, 110-112.

Lewis BS, Harding JJ, The effects of amino guanidine on the glycation (nonenzymatic glycosylation) of lens proteins, Exp Eye Res, 1990, 50, 463-467.


Refbacks

  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »
  • »


 

Int.J.Bioassays is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

Creative Commons License